FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310163410> ?p ?o ?g. }

• W4310163410 endingPage "7109" @default.
• W4310163410 startingPage "7108" @default.
• W4310163410 abstract "Introduction: Mezigdomide (BMS-986348) is a novel cereblon (CRBN) E3 ligase modulator (CELMoD®) that induces potent degradation of IKZF1 (Ikaros) and IKZF3 (Aiolos), transcription factors that contribute to multiple myeloma (MM) survival. The direct tumoricidal effect of mezigdomide is mediated by rapid, deep, and sustained degradation of Ikaros and Aiolos and induction of apoptosis in MM cells. In parallel, mezigdomide induces degradation of Ikaros and Aiolos in peripheral blood mononuclear cells (PBMCs), leading to the activation of T cells. This dual mechanism of cell-autonomous tumor inhibition and immune activation has been invoked to explain the clinical observations highlighting the impact of patient immune status on treatment outcomes. Here, we provide data indicating that these mechanisms may be one and the same: the primary site of action of mezigdomide is in the tumor cell, and results in both cell-autonomous viability loss and sensitization to immune-mediated killing. Methods: To assess the impact of mezigdomide on interactions with T cells, we combined mezigdomide and alnuctamab (BMS-986349; CC-93269), an asymmetric 2-arm, humanized immunoglobulin G1-based T-cell engager that promotes T-cell-mediated killing of target cells by recruiting T cells to BCMA-expressing target cells, leading to immune-synapse formation and T-cell cytotoxic activity. Donor T cells (n = 3) or target MM cells (n = 3 cell lines with various BCMA-expression levels tested: H929 > OPM2 > L363) were pretreated with mezigdomide for 16 or 72 hours, respectively, and after mezigdomide wash off, T cells and MM cells were combined in a co-culture system followed by alnuctamab treatment for 72 hours. BCMA was measured before and after mezigdomide pretreatment. Target-cell viability, T-cell proliferation, and cytokine release were measured at the end of the co-culture period. Primity BioScreen, a flow-cytometry-based assessment of membrane-associated proteins, was performed on target MM cells (n = 5 different cell lines) and PBMCs following mezigdomide pretreatment to profile potential changes in surface proteins important for immune-synapse formation. Results: Pretreatment of target MM cells with mezigdomide for 72 hours led to enhanced cytotoxic activity of alnuctamab. These results were reproducible across 3 healthy donors and various MM cell lines, including lenalidomide- and pomalidomide-resistant derivates, but not in CRBN-deficient cell lines. Profiling of secreted factors associated with T-cell cytotoxic function revealed increased release of interleukin-2 after mezigdomide pretreatment of either T cells only or T cells and MM cells; further experiments utilizing conditioned media showed no effect of mezigdomide-induced secreted factors on T-cell-mediated killing, suggesting a primary role for T-cell-to-target-cell interaction. Primity BioScreen revealed that the profile of adhesion molecules important for T-cell-mediated killing had been shifted both in MM cells and in PBMCs after mezigdomide pretreatment, revealing several candidates potentially mediating the enhanced cytotoxicity of alnuctamab following mezigdomide pretreatment. Conclusions: Collectively, our data demonstrate that pretreatment with mezigdomide induces enhanced immune sensitization in MM cells via upregulation of membrane-associated cell-adhesion molecules leading to increased cytotoxic T-cell activity. These results support the clinical investigation of mezigdomide in combination with T-cell-engaging therapeutic modalities in patients with MM." @default.
• W4310163410 created "2022-11-30" @default.
• W4310163410 creator A5003872699 @default.
• W4310163410 creator A5007024868 @default.
• W4310163410 creator A5021019265 @default.
• W4310163410 creator A5037376307 @default.
• W4310163410 creator A5039907595 @default.
• W4310163410 creator A5057732543 @default.
• W4310163410 creator A5068212123 @default.
• W4310163410 creator A5069870180 @default.
• W4310163410 creator A5070175640 @default.
• W4310163410 creator A5088108919 @default.
• W4310163410 creator A5091104294 @default.
• W4310163410 date "2022-11-15" @default.
• W4310163410 modified "2023-10-12" @default.
• W4310163410 title "Mezigdomide (CC-92480), a Novel Cereblon E3 Ligase Modulator, Induces Vulnerability of Multiple Myeloma Cells to T-Cell-Mediated Killing" @default.
• W4310163410 doi "https://doi.org/10.1182/blood-2022-157939" @default.
• W4310163410 hasPublicationYear "2022" @default.
• W4310163410 type Work @default.
• W4310163410 citedByCount "1" @default.
• W4310163410 countsByYear W43101634102023 @default.
• W4310163410 crossrefType "journal-article" @default.
• W4310163410 hasAuthorship W4310163410A5003872699 @default.
• W4310163410 hasAuthorship W4310163410A5007024868 @default.
• W4310163410 hasAuthorship W4310163410A5021019265 @default.
• W4310163410 hasAuthorship W4310163410A5037376307 @default.
• W4310163410 hasAuthorship W4310163410A5039907595 @default.
• W4310163410 hasAuthorship W4310163410A5057732543 @default.
• W4310163410 hasAuthorship W4310163410A5068212123 @default.
• W4310163410 hasAuthorship W4310163410A5069870180 @default.
• W4310163410 hasAuthorship W4310163410A5070175640 @default.
• W4310163410 hasAuthorship W4310163410A5088108919 @default.
• W4310163410 hasAuthorship W4310163410A5091104294 @default.
• W4310163410 hasBestOaLocation W43101634101 @default.
• W4310163410 hasConcept C104317684 @default.
• W4310163410 hasConcept C134459356 @default.
• W4310163410 hasConcept C153911025 @default.
• W4310163410 hasConcept C175114707 @default.
• W4310163410 hasConcept C185592680 @default.
• W4310163410 hasConcept C203014093 @default.
• W4310163410 hasConcept C25602115 @default.
• W4310163410 hasConcept C2776364478 @default.
• W4310163410 hasConcept C2778540781 @default.
• W4310163410 hasConcept C2908868211 @default.
• W4310163410 hasConcept C502942594 @default.
• W4310163410 hasConcept C54355233 @default.
• W4310163410 hasConcept C552990157 @default.
• W4310163410 hasConcept C71924100 @default.
• W4310163410 hasConcept C86803240 @default.
• W4310163410 hasConceptScore W4310163410C104317684 @default.
• W4310163410 hasConceptScore W4310163410C134459356 @default.
• W4310163410 hasConceptScore W4310163410C153911025 @default.
• W4310163410 hasConceptScore W4310163410C175114707 @default.
• W4310163410 hasConceptScore W4310163410C185592680 @default.
• W4310163410 hasConceptScore W4310163410C203014093 @default.
• W4310163410 hasConceptScore W4310163410C25602115 @default.
• W4310163410 hasConceptScore W4310163410C2776364478 @default.
• W4310163410 hasConceptScore W4310163410C2778540781 @default.
• W4310163410 hasConceptScore W4310163410C2908868211 @default.
• W4310163410 hasConceptScore W4310163410C502942594 @default.
• W4310163410 hasConceptScore W4310163410C54355233 @default.
• W4310163410 hasConceptScore W4310163410C552990157 @default.
• W4310163410 hasConceptScore W4310163410C71924100 @default.
• W4310163410 hasConceptScore W4310163410C86803240 @default.
• W4310163410 hasIssue "Supplement 1" @default.
• W4310163410 hasLocation W43101634101 @default.
• W4310163410 hasOpenAccess W4310163410 @default.
• W4310163410 hasPrimaryLocation W43101634101 @default.
• W4310163410 hasRelatedWork W1998215017 @default.
• W4310163410 hasRelatedWork W2112142795 @default.
• W4310163410 hasRelatedWork W2121772170 @default.
• W4310163410 hasRelatedWork W2161413435 @default.
• W4310163410 hasRelatedWork W2797773019 @default.
• W4310163410 hasRelatedWork W2917115789 @default.
• W4310163410 hasRelatedWork W4237352384 @default.
• W4310163410 hasRelatedWork W4240274584 @default.
• W4310163410 hasRelatedWork W4242752272 @default.
• W4310163410 hasRelatedWork W4303954706 @default.
• W4310163410 hasVolume "140" @default.
• W4310163410 isParatext "false" @default.
• W4310163410 isRetracted "false" @default.
• W4310163410 workType "article" @default.